

****Published June 2014****

MarketVIEW: Rotavirus vaccines (CAT: VAMV057)

Product Name	:	MarketVIEW: Rotavirus vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation + 1 forecast model
Therapeutic Area	:	Pediatric vaccines
Publication date	:	June 2014
Catalogue No	:	VAMV057

Background

Rotavirus, transmitted by the faecal oral route causes fever and vomiting followed by diarrhoea/dehydration in neonates and infants. Recovery is usually complete but in the developing world, the virus is responsible for 5% of all deaths among children below five yrs (453,000 deaths in 2008).

Improvements in water quality and sanitation do not adequately prevent the spread of rotavirus such that vaccination is the best way to prevent severe infection. In 2009, the WHO recommended that rotavirus vaccines be included in all national immunisation programs and considered a priority. Two rotavirus vaccines, Rotarix (GSK Biologicals) and Rotateq (Merck & Co) have been licensed since 2006 and are used in both Western and developing world countries. New rotavirus vaccines are in development which may address the limitations of Rotarix and Rotateq.

This **MarketVIEW** product is a comprehensive commercial opportunity assessment detailing the current and potential market for Rotavirus vaccine(s) using a patient based value/volume forecast for major Western markets, BRIC-MIT and GAVI countries to 2030. The forecast gives revenues and volume shares per vaccine per region taken into account the launch of new products and roll out into GAVI countries. The analysis also provides an update on competitor R&D activity and includes a detailed update of country national immunisation program parameters to date.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to rotavirus vaccines. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of paediatricines has also been utilised. ***See Bibliography for exact sources.

PRODUCT CONTENTS:

Published June 2014 (CAT No: VAMV057)

****This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

Authors Note

Executive summary

Commercial model: key outputs

Rotavirus vaccines: global forecast revenue (\$m) to 2030

Rotavirus vaccines: global forecast volume (000s doses) to 2030

Rotavirus vaccines: volume (000s doses) by country and vaccine – Major Western to 2030

Rotavirus vaccines: revenue (\$m) by country and vaccine – Major Western to 2030

Rotavirus vaccines: volume (000s doses) by country and vaccine – BRICMIT to 2030

Rotavirus vaccines: revenue (\$m) by country and vaccine – BRICMIT to 2030

Rotavirus vaccines: volume (000s doses) by WHO region and vaccine – GAVI to 2030

Rotavirus vaccines: revenue (\$m) by WHO region and vaccine – GAVI to 2030

Rotavirus vaccines: market share by country and region in 2020*

Rotavirus vaccines: market share (volume and value) by vaccine in 2020*

Rotavirus vaccines: volume and revenue breakdown of 'Other' vaccines to 2030

Rotavirus: disease background and epidemiology

Rotavirus: the pathogen

Rotavirus transmission

Rotavirus diarrhoea

Protective immunity against rotavirus infection

Rotavirus: prevalence and incidence worldwide

Mortality associated with rotavirus

The global burden of RV diarrhoeal disease

Countries with the highest burden of RV-related deaths

Rotavirus: at-risk groups

Age distribution of rotavirus infections in children aged <5 years, 2000–2011, England and Wales

Prevention of RV disease

Rotavirus vaccines: the current products and markets

Rotarix (GSK)

RotaTeq (Merck & Co)

WHO guidelines on rotavirus vaccination

National immunisation programmes – USA, Canada, Australia

National immunisation programmes – 5EU

National immunisation programmes – BRIC and MINT countries

Continued.....

GAVI-supported RV vaccine introductions by WHO region: 26 countries
National RV vaccine introductions by WHO region: 59 countries.
Coverage of national vaccination programmes.
New rotavirus vaccines: overview of current R&D
The need for new rotavirus vaccines
Rotavirus vaccine: ideal target product profiles
Live rotavirus vaccines in development
Non-replicating rotavirus vaccines
Rotavirus vaccines: Modelling the current market
Modelling methodology: overview
New product launch assumptions
Model inputs – USA, Canada, Australia
Model inputs – 5EU
Model inputs – BRIC
Model inputs – MINT
Model inputs – GAVI countries
WHO regions (as used in GAVI models)
Bibliography
Disclaimer
About **VacZine Analytics**

PAGES: 65 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based) – 1 model

Title sheet
CHARTS - global
CHARTS - major Western (5EU +3)
CHARTS - BRICMIT
CHARTS – GAVI
MS by country or region
MS by vaccine
MS other
Vol Val global
Vol Val 5EU+3
Vol Val GAVI
US
Canada
United Kingdom
France
Germany
Italy
Spain
Australia
Brazil
Russia.
India.
China
Mexico
Indonesia.



Continued.....

Turkey
GAVI Africa
GAVI AMR + EMR
GAVI EUR+SEAR+WPR
Birth cohorts
Infant mortality
Assumptions
Backpage

WORKSHEETS: ~30

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$8995.00**/ GBP **£5450.00**[#] (Region license)*
- PRESENTATION OR MODEL ONLY - USD **\$4995.00** (Region license)*

[#] Indicative rate only. Prevailing rate applied to date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY:

1. Kim SY et al. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC. Pub. Health 2010;10:253
2. Patton JT. Rotavirus diversity and evolution in the post-vaccine world. Discov. Med. 2012;13:85
3. World Health Organization. Rotavirus vaccines, WHO position paper – January 2013. Weekly Epidemiological Record 2013;88:49
4. Atchison CJ et al. Temperature-dependent transmission of rotavirus in Great Britain and The Netherlands. Proc. R. Soc. B 2010;277:933
5. Health Protection Agency. Laboratory reports of rotavirus infections in England and Wales, by month of report, 2000-2012. 2012. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Rotavirus/EpidemiologicalData/rota_DataEwMonth/ Accessed May 2014
6. Hrdy DB. Epidemiology of rotaviral infection in adults. Rev. Infect. Dis. 1987;9:461
7. GAVI Alliance. Rotavirus vaccine support. 2014. <http://www.gavialliance.org/support/nvs/rotavirus/> Accessed May 2014
8. Tate JE et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 2012;12:136
9. Ryan MJ et al. Hospital admissions attributable to rotavirus infection in England and Wales. J. Infect. Dis. 1996;174(Suppl 1):S12
10. Health Protection Agency. Laboratory reports of rotavirus infections in England and Wales, by age group, 2000-2012. 2012. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Rotavirus/EpidemiologicalData/rota_DataEwAge/ Accessed May 2014
11. Public Health England. Rotavirus: the green book, chapter 27b. 2013. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/254913/Green_Book_Chapter_27b_v2_0.pdf Accessed May 2014
12. GSK. Rotarix Summary of Product Characteristics. 2013.
13. Grimwood K & Lambert SB. Rotavirus vaccines: opportunities and challenges. Hum. Vacc. 2009;5:57
14. European Medicines Agency. Rotarix. 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000639/human_med_001043.jsp&mid=WCOb01ac058001d124 Accessed May 2014
15. Food and Drug Administration. Rotarix 2010. <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm133544.htm> Accessed May 2014
16. Soares-Weiser K et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst. Rev. 2012;11:CD008521
17. Merck. RotaTeq Summary of Product Characteristics. 2013.
18. European Medicines Agency. RotaTeq. 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000669/human_med_001045.jsp&mid=WCOb01ac058001d124 Accessed May 2014
19. Food and Drug Administration. RotaTeq. 2013. <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094063.htm> Accessed May 2014
20. Cortese MM & Parashar UD. Prevention of Rotavirus Gastroenteritis Among Infants and Children Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recc. Rep. 2009;58(RR02):1
21. CBC News. 2012. <http://www.cbc.ca/news/health/baby-rotavirus-vaccine-bill-should-be-covered-1.1218786> Accessed May 2014
22. NCIRS. Rotavirus factsheet. 2013. <http://www.ncirs.edu.au/immunisation/fact-sheets/rotavirus-fact-sheet-November-2013.pdf> Accessed May 2014
23. European Centre for Disease Prevention and Control. Vaccine schedule. 2014. <http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx> Accessed May 2014
24. STIKO. Recommendation for routine rotavirus vaccination of infants in Germany. 2013. http://www.rki.de/DE/Content/Infekt/Impfen/Forschungsprojekte/Rotavirus-Impfung/BGBL_56_2013.pdf?__blob=publicationFile Accessed May 2014
25. Ikeda do Carmo GM et al. Decline in Diarrhea Mortality and Admissions after Routine Childhood Rotavirus Immunization in Brazil: A Time-Series Analysis. PLoS Med. 2011;8:e1001024
26. St. Petersburg Times. Russia To Begin Nationwide Vaccination Against Rotavirus. 2013. http://sptimes.ru/index_bp.php?action_id=2&story_id=37549§ion=14 Accessed May 2014
27. Bhandari N et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 2014 [Epub ahead of print]

28. Fu C et al. Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children. *Vaccine* 2012;31:154
29. He Q et al. Rotavirus Vaccination Coverage among Children Aged 2-59 Months: A Report from Guangzhou, China. *PLoS One* 2013;8:e68169
30. Richardson V et al. Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico. *N. Engl. J. Med.* 2010;362:299
31. Bines J. After 40 Years, a Rotavirus Vaccine for Newborns Is in Sight. 2013. <http://www.impatientoptimists.org/Posts/2013/08/After-40-Years-a-Rotavirus-Vaccine-for-Newborns-Is-in-Sight> Accessed May 2014
32. ROTA Council. Nigeria yet to procure vaccine against rotavirus. 2014. <http://rotacouncil.org/news/nigeria-yet-to-procure-vaccine-against-rotavirus/> Accessed May 2014
33. Bakir M et al. Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model. *Vaccine* 2013;31:979
34. PATH. Country introductions of rotavirus vaccines. Maps and list. 2014. <http://sites.path.org/rotavirusvaccine/rotavirus-advocacy-and-communications-toolkit/country-introduction-maps-and-list/> Accessed May 2014
35. National, State, and Local Area Vaccination Coverage Among Children Aged 19–35 Months — United States, 2012. *MMWR* 2013;62:733
36. Public Health England. Health Protection Report Weekly Report. 2014;8(12)
37. Orozco M et al. Uptake of Rotavirus Vaccine and National Trends of Acute Gastroenteritis among
38. Hull BP et al. Impact of the introduction of rotavirus vaccine on the timeliness of other scheduled vaccines: the Australian experience. *Vaccine* 2013;31:1964
39. Flannery B et al. Uptake of oral rotavirus vaccine and timeliness of routine immunization in Brazil's National Immunization Program. *Vaccine* 2013;31:1523
40. Atherly DE et al. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011–2030. *Vaccine* 2012;30S:A7
41. Ustrup M et al. Outstanding challenges for rotavirus vaccine introduction in low-income countries – a systematic review. *Dan. Med. Bul.* 2011;58:A4323
42. Bines J. RV3 rotavirus vaccine. 2013. http://www.sabin.org/sites/sabin.org/files/Julie%20Bines%20RV3_web.pdf Accessed May 2014
43. CIDRAP. 2014. <http://www.cidrap.umn.edu/news-perspective/2014/03/phase-3-results-boost-rotavirus-vaccine-developed-india> Accessed May 2014
44. Business Wire. International Medica Foundation Sublicenses First Rotavirus Vaccine for Newborns in China. 2013. <http://finance.yahoo.com/news/international-medica-foundation-sublicenses-first-145100907.html> Accessed May 2014
45. PATH. Exploring new, non-replicating rotavirus vaccines. 2013. http://www.path.org/publications/files/VAC_nrrv_fs.pdf Accessed May 2014
46. PATH. Live rotavirus vaccine development. 2014. <http://sites.path.org/vaccinedevelopment/diarrhea-rotavirus-shigella-etec/live-rotavirus-vaccine-development/> Accessed May 2014
47. Clinicaltrials.gov. 2014. <http://clinicaltrials.gov/ct2/show/NCT02133690> Accessed May 2014
48. Clinicaltrials.gov. 2010. <http://clinicaltrials.gov/ct2/show/NCT01061658> Accessed May 2014
49. Danchin M et al. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. *Vaccine* 2013;31:2610
50. Estes MK. Developing Next Generation Rotavirus Vaccines: Prospects from the Pipeline to Address Remaining Public Health Needs. 2014. http://www.who.int/immunization/research/forums_and_initiatives/01_Parashar_Estes_Neuzil_GVIRF14_Dev_next_generation.pdf Accessed May 2014
51. Panozzo CA et al. Patterns of Rotavirus Vaccine Uptake and Use in Privately-Insured US Infants, 2006–2010. *PLoS One* 2013;8:e73825
52. CDC Vaccine Price List. 2014. http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html?s_cid=cs_000 Accessed May 2014
53. PHAC. Vaccine Coverage in Canadian Children: Results from the 2011 Childhood National Immunization Coverage Survey. 2014. <http://www.phac-aspc.gc.ca/im/nics-enva/vccc-cvec-eng.php> Accessed May 2014
54. Coyle D et al. Cost effectiveness of infant vaccination for rotavirus in Canada. *Can. J. Infect. Dis. Med. Microbiol.* 2012;23:71
55. Newall AT et al. The cost-effectiveness of rotavirus vaccination in Australia. *Vaccine* 2007;25:8851
56. Jit M et al. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. *Vaccine* 2009;27:6121
57. Aidelsburger P et al. Cost-effectiveness of childhood rotavirus vaccination in Germany. *Vaccine* 2014;32:1964
58. Dudareva-Vizule S et al. Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany. *Hum. Vacc. Immunother.* 2012;8:1407

59. Vitale F et al. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy]. *Ann. Ig.* 2013;25:43
60. Perez-Rubio A et al. Socio-economic modelling of rotavirus vaccination in Castilla y León, Spain. *Infez. Med.* 2011;3:166
61. NHS Choices. Rotavaccine to be introduced for babies. 2012. <http://www.nhs.uk/news/2012/11November/Pages/New-vaccine-to-prevent-rotavirus-diarrhoea-in-babies.aspx> Accessed May 2014
62. Jit M & Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. *Vaccine* 2007;25:3971
63. Ikeda do Carmo GM et al. Decline in Diarrhea Mortality and Admissions after Routine Childhood Rotavirus Immunization in Brazil: A Time-Series Analysis. *PLoS Med.* 2011;8:e1001024
64. Constenla DO et al. Economic impact of a rotavirus vaccine in Brazil. *J. Health Popul. Nutr.* 2008;26:388
65. Kostinov MP & Zverev VV. [Economic effectiveness of vaccination against rotavirus infection in the Russian Federation]. *Zh. Mikrobiol. Epidemiol. Immunobiol.* 2012;3:50
66. Liu N et al. Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China. *Vaccine* 2012;30:6940
67. Esparza-Aguilar M et al. Diarrhoea-related hospitalizations in children before and after implementation of monovalent rotavirus vaccination in Mexico. *Bull. World. Health. Organ.* 2014;92:117
68. Constenla D et al. Economic impact of a rotavirus vaccination program in Mexico. *Rev. Panam. Salud. Publica.* 2009;25:481
69. Suwantika AA & Postma MJ. Effect of breastfeeding promotion interventions on cost-effectiveness of rotavirus immunization in Indonesia. *BMC Pub. Health* 2013;13:1106
70. Koksai AO & Koksai T. [The information level of parents about rotavirus gastroenteritis and rotavirus vaccine and the incidence of rotavirus vaccination in Ankara] *Gaziantep Med. J.* 2012;18:151
71. GAVI Alliance. Graduating countries. 2014. <http://www.gavialliance.org/support/apply/graduating-countries/> Accessed May 2014
72. PATH. Country National Immunization Program (NIP) Introductions of Rotavirus Vaccine. 2014. <http://sites.path.org/rotavirusvaccine/files/2014/05/PATH-Country-Introduction-Table.pdf> Accessed May 2014
73. Neuzil KM. Evaluation of the next generation of rotavirus vaccines. 2014. http://www.who.int/immunization/research/forums_and_initiatives/01_Parashar_Estes_Neuzil_GVIRF14_Dev_next_generation.pdf Accessed May 2014
74. GAVI Alliance secures lower price for rotavirus vaccine. 2012. <http://www.gavialliance.org/library/news/press-releases/2012/gavi-secures-lower-price-rotavirus-vaccine/> Accessed May 2014
75. Merck. Merck Commends GAVI Alliance on Continued Efforts to Improve Access. 2011. <http://www.mercknewsroom.com/press-release/corporate-responsibility-news/merck-commends-gavi-alliance-continued-efforts-improve-a> Accessed May 2014

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009

FOLLOW US ON TWITTER @VACZINEANALYTIC

Signup to our newsletter ExpertREACT - <http://www.vacZine-analytics.com/products-expertreact.asp>